1987
DOI: 10.1159/000118363
|View full text |Cite
|
Sign up to set email alerts
|

Chronic Treatment with Imipramine Does Not Reverse the Effects of 3 Anxiogenic Compounds in a Test of Anxiety in the Rat

Abstract: The ability of chronic treatment with imipramine (an antidepressant with anti-panic activity) to antagonise the anxiogenic effects of 3 different compounds was investigated in the elevated plus-maze. The compounds chosen are likely to produce anxiety by activity at different sites in the central nervous system: yohimbine, by blocking the α2-adrenoceptor; FG 7142, by action at the β-carboline site on the GABA-benzodiazepine receptor complex and pentylenetetrazole, by acting at the picrotoxinin site on this comp… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
6
0

Year Published

1989
1989
2019
2019

Publication Types

Select...
6
3

Relationship

0
9

Authors

Journals

citations
Cited by 33 publications
(8 citation statements)
references
References 15 publications
2
6
0
Order By: Relevance
“…Imipramine, on the other hand, did not alter measures loading on factor 1. These results agree with other negative ones obtained in rats exposed to the plus-maze and treated with IM either acutely (3,29) or chronically (30). Taken together, the effects of CDP, PTZ, and APO seem to indicate that only motor activity enhancement is not enough to explain how the measures loading on factor 1 were altered.…”
Section: Discussionsupporting
confidence: 92%
“…Imipramine, on the other hand, did not alter measures loading on factor 1. These results agree with other negative ones obtained in rats exposed to the plus-maze and treated with IM either acutely (3,29) or chronically (30). Taken together, the effects of CDP, PTZ, and APO seem to indicate that only motor activity enhancement is not enough to explain how the measures loading on factor 1 were altered.…”
Section: Discussionsupporting
confidence: 92%
“…However, inconsistencies have been found with animal models of anxiety. In the EPM, chronic treatment with imipramine does not have reliable anxiolytic effects (Cole and Rodgers, 1995;File and Johnston, 1987). However, in the elevated T-maze, the same treatment has been shown to impair both inhibitory avoidance of the open arms and one-way open-arm escape, two tasks supposedly related to generalized anxiety disorder and panic disorder, respectively (Borsini et al, 2002;Dombrowski and Andreatini, 2006;Teixeira et al, 2000).…”
Section: Introductionmentioning
confidence: 99%
“…This Þnding was later widely conÞrmed by other studies using either imipramine (Zitrin et al 1980;Sheehan et al 1980;Mavissakalian and Perel 1989) or other tricyclic antidepressant drugs (TCAs; Beaumont 1977;Muskin and Fryer 1981;Pecknold et al 1982). Nevertheless, the mechanism of action of imipramine in this disease is unknown and its study was impeded by the lack of e¤ects of long-term imipramine treatment in classical animal models of anxiety such as the potentiated startle (Cassella and Davis 1985), the defensive burying (Beardslee et al 1990), the social interaction (Pellow and File, 1987) and the elevated-plus maze tests (File and Johnston 1987;Cole and Rodgers 1995). However, in other recent studies, long-term imipramine was shown to display antipanic-like e¤ects in animal paradigms involving defense behaviours in response to conßict or predator stimuli (Bodno¤ et al 1988;Fontana and Commissaris 1988;Hendrie and Neill 1991;Blanchard et al 1993;Griebel et al 1995).…”
Section: Introductionmentioning
confidence: 99%